Latest news
AMiner Finds Ligand Reconstruction Cuts Defects In Quantum Dot Light Emitters - Quantum ZeitgeistQuantum Zeitgeist · Fri, 07 Aug 2026 21:51:46 GMTLigand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In? - simplywall.stsimplywall.st · Fri, 07 Aug 2026 07:41:02 GMTLigand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ... - Yahoo! Finance CanadaYahoo! Finance Canada · Thu, 06 Aug 2026 23:18:35 GMT(LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21 - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 12:07:37 GMTLigand Reports Second Quarter 2026 Financial Results - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 11:19:22 GMTLigand Adds More Than 120 Royalty Assets in XOMA Acquisition - Stock TitanStock Titan · Thu, 06 Aug 2026 11:08:47 GMTImmunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2/neu Status: A Single-Centre Study From Central India - CureusCureus · Wed, 05 Aug 2026 14:36:24 GMTOppenheimer Adjusts Ligand Pharmaceuticals PT to $326 From $285, Maintains Outperform Rating - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 13:13:33 GMT